Journal
ONCOTARGET
Volume 8, Issue 24, Pages 39177-39184Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16640
Keywords
long noncoding RNA; ANRIL; lung adenocarcinoma; chemotherapy resistance; paclitaxel
Categories
Funding
- Doctoral Research Initiation Foundation of Liaoning Province [201601121]
Ask authors/readers for more resources
Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs that might affect Lung adenocarcinoma (LAD) chemo-resistance and most of them could be used as biomarkers and therapy targets. However, the potential function of lncRNA ANRIL contributed paclitaxel chemo-resistance in LAD is still unknown. This study aimed to observe the expression of ANRIL in LAD, evaluate its biological role in the resistance of LAD cells to paclitaxel and explore the apoptosis role in the ANRIL associated mechanism. Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2. These findings might improve LAD patients' paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available